Hong Kong consensus defines when to consider local ablative therapy in oncogene-driven NSCLC

The Hong Kong SBRT Study Group recommends risk-adapted local therapy for selected oncogene-driven NSCLC, including oligoresidual, oligoprogressive, and intracranial disease.

KEY POINTS

  • The Hong Kong SBRT Study Group developed 23 consensus statements addressing local ablative therapy (LAT) for oligometastatic NSCLC harboring actionable molecular alterations, including EGFR, ALK, ROS1, RET, MET, BRAF, and others. A multidisciplinary working group reviewed publications from January 2014 through June 2026 and used a modified Delphi process, defining consensus as ≥75% agreement. Recommendations were not assigned formal evidence-strength grades because of the heterogeneity and limited randomized evidence.
  • The panel defined oligometastatic and oligoprogressive disease using a threshold of five extracranial metastases. Oligometastatic disease includes up to five extracranial lesions, either at initial diagnosis or following systemic treatment. Oligoresidual disease refers to up to five persistent lesions after systemic treatment, typically assessed after at least three months, while oligoprogression refers to up to five progressing lesions during otherwise effective treatment. Comprehensive staging should preferably include FDG PET/CT and brain MRI, and diffuse serosal involvement, malignant effusions, and leptomeningeal metastases exclude the proposed oligometastatic classification.
  • Patient selection should prioritize performance status, treatability of all active sites, and multidisciplinary review. The panel reached 100% agreement that LAT should be considered in patients with ECOG performance status ≤2, provided treatment of all known disease sites is feasible and safe. SBRT or hypofractionated image-guided RT are generally preferred radiation approaches when appropriate. However, the optimal dose and fractionation remain undefined, and organ-at-risk constraints should take priority over unrestricted dose escalation, particularly for central thoracic lesions or multiple targets within one organ.
  • LAT may be considered upfront, after targeted therapy, or at oligoprogression, but the optimal sequence remains uncertain. Consensus agreement was 90% for upfront treatment, 95% for consolidation, and 100% for treatment at progression. The panel cited randomized data supporting LAT in selected populations, including SINDAS, where upfront SBRT plus first-generation EGFR inhibitors improved median progression-free survival from 12.5 to 20.2 months and overall survival from 17.4 to 25.5 months. Nevertheless, many supporting studies predate contemporary targeted regimens, and the panel could not establish a universally preferred treatment sequence.
  • The panel recommended individualized management of targeted agents around SBRT. A brief treatment interruption before and after SBRT may be considered according to the drug, anatomical site, and expected toxicity, while continuation of the same targeted agent after LAT is reasonable in selected patients with controlled extracranial disease. Concurrent thoracic RT and tyrosine kinase inhibitors warrant particular caution: a cited meta-analysis reported severe pneumonitis in 4.9% with concurrent treatment versus 0.4% with sequential therapy. No universal interruption interval was established, especially for newer agents and non-EGFR molecular targets.
  • Intracranial recommendations distinguish targeted agents with strong CNS activity from those with uncertain activity. For patients with four or fewer brain metastases receiving a drug with uncertain intracranial efficacy, upfront local therapy should be considered. If an effective CNS-active agent is available and brain metastases are asymptomatic or mildly symptomatic, initial local treatment may be deferred with surveillance. After local treatment of oligoprogressive brain lesions, continuation of the same systemic therapy may be appropriate when extracranial disease remains controlled. All three recommendations achieved 100% consensus.
  • The recommendations remain conditional on disease biology and contemporary systemic treatment options. Much of the evidence originates from EGFR-mutated cohorts, with fewer data for ALK and other actionable alterations. The panel also noted that indirect comparisons with systemic intensification studies such as FLAURA2 and MARIPOSA cannot establish that LAT is an equivalent alternative. Optimal timing, radiation dose, treatment interruptions, and the long-term effects of combining SBRT with modern targeted agents require prospective evaluation.

CLINICAL TAKEAWAY

The Hong Kong consensus provides a structured approach to integrating SBRT and other local ablative treatments with targeted therapy in selected patients with oncogene-driven oligometastatic NSCLC. Its most actionable recommendations concern comprehensive staging, treatment of all feasible disease sites, individualized sequencing, and caution when combining thoracic irradiation with targeted agents. However, these are expert consensus statements, and many recommendations remain supported by heterogeneous or nonrandomized evidence.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction